ALTUVIIIO

STN: 125771
Proper Name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
Tradename: ALTUVIIIO
Manufacturer: Bioverativ Therapeutics Inc., a Sanofi Company
Indication:

For use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

1. Routine prophylaxis to reduce the frequency of bleeding episodes; 
2. On-demand treatment and control of bleeding episodes; and 
3. Perioperative management of bleeding.

Product Information

Supporting Documents